Patents Represented by Attorney, Agent or Law Firm Anthony D. Sabatelli
  • Method for inhibiting bone resorption
    Patent number: 6015801
    Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for caring out the therapeutic methods disclosed herein.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: January 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Anastasia G. Daifotis, A. John Yates, Arthur C. Santora, II
  • Anhydrous alendronate monosodium salt formulations
    Patent number: 6008207
    Abstract: Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical doage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: December 28, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Gerald S. Brenner, Drazen Ostovic, Earl R. Oberholtzer, Jr., J. Eric Thies
  • Sodium alendronate preparation for local administration
    Patent number: 6008206
    Abstract: The object of the present invention is to provide a preparation for local administration to permit selective delivery of an effective amount of sodium alendronate to the bone site where bone resorption is accentuated.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: December 28, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Masahiko Dohi, Yuji Makino, Takao Hujii
  • Method for inhibiting bone resorption
    Patent number: 5994329
    Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: November 30, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Anastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
  • Integrin antagonists
    Patent number: 5981546
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
    Type: Grant
    Filed: August 18, 1997
    Date of Patent: November 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman, William F. Hoffman, Robert S. Meissner, James J. Perkins, Ben C. Askew, Paul J. Coleman, John H. Hutchinson, Adel M. Naylor-Olsen
  • Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
    Patent number: 5972913
    Abstract: Disclosed is a therapy for treating and for preventing periprosthetic bone loss by the administration of a bisphosphonate bone resorption inhibitor, e.g., alendronate, in patients who have an orthopedic implant device.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: October 26, 1999
    Assignee: Merck & Co., Inc.
    Inventor: Ashley J. Yates
  • Sodium alendronate preparation for local administration
    Patent number: 5958908
    Abstract: The present invention provides a method local administration of an effective amount of sodium alendronate to permit selective delivery to the bone site where bone resorption is accentuated.
    Type: Grant
    Filed: April 13, 1998
    Date of Patent: September 28, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Masahiko Dohi, Yuji Makino, Takao Hujii
  • Integrin antagonists
    Patent number: 5952341
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: September 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman
  • .alpha..sub.v .beta..sub.3 antagonists
    Patent number: 5925655
    Abstract: This invention relates to certain novel isoindolone compounds and derivatives thereof, their synthesis, and their use as .alpha.v.beta.3 receptor antagonists. The .alpha.v.beta.3 receptor antagonist compounds of this invention are useful for inhibiting bone resorption, treating and preventing osteoporosis and cancer, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: July 20, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman, William F. Hoffman
  • Integrin antagonists
    Patent number: 5919792
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: July 6, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman, William F. Hoffman, Nathan C. Ihle
  • Intravenous alendronate formulations
    Patent number: 5914323
    Abstract: Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.
    Type: Grant
    Filed: May 5, 1998
    Date of Patent: June 22, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Gerald S. Brenner, Musa M. Ghannam
  • Prevention of tooth loss by the administration of alendronate or its salts
    Patent number: 5914099
    Abstract: Alendronate, a bisphosphonate can prevent tooth loss not necessarily associated with periodontal disease. Preferably, alendronate (or a pharmaceutically acceptable salt thereof) is given daily for an extended period of time.
    Type: Grant
    Filed: November 4, 1997
    Date of Patent: June 22, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Ashley John Yates, David B. Karpf
  • Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
    Patent number: 5891863
    Abstract: Disclosed is a therapy for treating and for preventing periprosthetic bone loss by the administration of a bisphosphonate bone resorption inhibitor, e.g., alendronate, in patients who have an orthopedic implant device.
    Type: Grant
    Filed: June 16, 1997
    Date of Patent: April 6, 1999
    Assignee: Merck & Co., Inc.
    Inventor: Ashley J. Yates
  • Dry mix formulation for bisphosphonic acids
    Patent number: 5882656
    Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: March 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Simon R. Bechard, Kenneth A. Kramer, Ashok V. Katdare
  • Effervescent alendronate formulation
    Patent number: 5853759
    Abstract: An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and optionally, flavoring agents, colorants and sweeteners.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: December 29, 1998
    Assignee: Merck & Co.. Inc.
    Inventors: Ashok V. Katdare, Kenneth A. Kramer, Colin R. Gardner
  • Anhydrous alendronate monosodium salt formulations
    Patent number: 5849726
    Abstract: Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical dosage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: December 15, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Gerald S. Brenner, Drazen Ostovic, Earl R. Oberholtzer, Jr., J. Eric Thies
  • Intravenous alendronate formulations
    Patent number: 5843924
    Abstract: Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: December 1, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Gerald S. Brenner, Musa M. Ghannam
  • Method of lessening the risk of non-vertebral bone fractures
    Patent number: 5804570
    Abstract: Alendronate, a bisphosphonate, when administered daily over a substantial period of time, can reduce the rate of non-vertebral fractures, in post-menopausal women.
    Type: Grant
    Filed: June 3, 1997
    Date of Patent: September 8, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Arthur C. Santora, II, David B. Karpf, William J. Polvino, Deborah Ruth Shapiro, Desmond E. Thompson, Ashley John Yates
  • Intravenous alendronate formulations
    Patent number: 5780455
    Abstract: Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.
    Type: Grant
    Filed: August 24, 1994
    Date of Patent: July 14, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Gerald S. Brenner, Musa M. Ghannam
  • Pharmaceutical tablet
    Patent number: D400672
    Type: Grant
    Filed: March 21, 1996
    Date of Patent: November 3, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth A. Kramer, Ashok V. Katdare